EVENTS & NEWS
April 1, 2020
The product Solnatide, developed by the Austrian company Apeptico Forschung und Entwicklung GmbH, is an investigational medicinal product for the treatment of various forms of life-threatening acute pulmonary dysfunction and pulmonary oedema in acute respiratory distress syndrome (ARDS) patients.
Now, thanks to this Grant Agreement with the European Comission, Solnatide will be available for medical treatment of patients severely affected by the novel coronavirus 2019 (SARS-CoV-2) disease, COVID-19.
In this emergency situation in hospitals across Europe, BCN PEPTIDES will manufacture Solnatide Active Pharmaceutical Ingredient for the therapeutic treatment of patients suffering from severe symptoms of infection with the SARS-CoV-2 novel coronavirus.
September 4, 2019
BCN Peptides included Atopic dermatitis in its research program. The project, enclosed in “Nuclis d’R+D empresarial” program from ACCIÒ, is cofinanced with the European Union FEDER funds.
March 12, 2019
The CataloniaBio & HealthTech night gathered more than 200 entrepreneurs, executives and investors from the biomedical field in the modernist enclosure of Sant Pau in Barcelona.
The jury of the Employers Awards has granted a prize to Dr. Antonio Parente recognizing his professional trajectory. The prize was awarded by Health Counsellor, Alba Vergès.
CataloniaBio & HealthTech recognized Dr. Antonio Parente, promoter of the Patronal in 2006, for his business trajectory. In 1987, Antonio Parente cofounded the Grupo Lipotec, which was sold years later in one of the biggest transactions of the, at that time, young Catalan biotech sector.
Nowadays Dr. Antonio Parente is President and founder of GP Pharm and BCN Peptides.
Dr. Antonio Parente highlighted that this award “wouldn´t have been possible without the business group´s professional human team”.